

## RECEIVED

Try My Greckie

PATENT

IN THE UNITED STATES (PATENT AND TRADEMARK OFFICE

In Re the Application GROUP 110

WILLIAM R. BARCLAY

Serial No.: 07/580,778

Filed: September 11, 1990

Atty. File No.: 2391-1

For: "PROCESS FOR THE HETER-OTROPHIC PRODUCTION OF MICROBIAL PRODUCTS WITH HIGH CONCENTRATIONS OF OMEGA-3 HIGHLY UNSAT-URATED FATTY ACIDS"

Group Art Unit:

Examiner:

PETITION TO MAKE SPECIAL

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

Applicant hereby petitions the Commissioner to make the above-identified application special pursuant Commissioner's announcement published in 1092 Inventor Barclav is the President of Phycotech. Colorado corporation having small entity assignment of the invention from William R. Barclay to a Verified Statement (Declaration) Phycotech, Inc. and claiming Small Entity Status were filed concurrently with the above-identified application.

The subject matter of the above-identified application is a major asset of Phycotech, Inc. The development of the technology disclosed by the application will be significantly impaired if examination of the application is delayed.

080 DF 10/31/90 07580778

CERTIFICATE OF MAILING I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, OC 20231
ON THIS 16<sup>Th</sup> DAY OF COLORER 19

Future business development of the company is in part predicated on patent protection to proceed with the further development of the disclosed organisms and methods of making and using them. Because the corporation is in its infancy, it is important for it to be able to disclose its technology to potential investors, licensees or joint venture partners with confidence in its proprietary position, in order to further develop and use the technology. The nature of the technology is such that, once disclosed, it is readily duplicated. Many uses of the technology are readily adaptable to being maintained in secret, especially by large entity competitors who do not need investors, licensees, or joint venture partners. For all of these reasons, future development of the company and of the technology will be significantly impaired if the examination of the patent application is delayed.

Pursuant to 37 C.F.R. §1.17(i)(2), the requisite \$80.00 filing fee is enclosed. Please credit any overpayment or debit any underpayment to Deposit Account No. 19-1970.

Respectfully submitted,
SHERIDAN, ROSS & McINTOSH

Date: October 16,1990

By:

Breight L. Speer

Registration Nd. 34,253

One United Bank Center

One United Bank Center 1700 Lincoln Street Thirty-Fifth Floor Denver, Colorado 80203 (303) 863-9700

LW/2391-1.RES/D1/BLS